An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan

Trial Profile

An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Elotuzumab (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Expanded access; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 04 Jan 2017 Status changed from recruiting to completed.
    • 30 Nov 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2016.
    • 30 Nov 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top